Status update
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 768 |
| Referral date | 01 December 2014 |
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Associate Director: | Helen Knight |
| Communications manager: | TBC |
| Project manager: | Kate Moore |
| Technical Advisor: | TBC |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 September 2022 | Suspended. Status update |
| 18 October 2016 | The Department of Health has asked us to carry out a Multiple Technology Appraisal of botulinum toxin type A preparations (Botox, Dysport, and Xeomin) within their marketing authorisations for treating upper or lower limb focal spasticity associated with stroke. This appraisal involves a number of companies and as the appraisal will be covering the treatment for upper or lower focal spasticity there are a broad range of licenses. NICE therefore has to ensure that all products will be licensed at the appropriate point in the appraisal. Taking all of these points into account and in order to undertake this appraisal efficiently whilst providing the best value to the NHS the appraisal will be rescheduled. The revised timelines will be available in due course. |
| 24 June 2015 | Please note that following on from updates received from some of the companies this appraisal has been rescheduled in order to align with the latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late January 2017when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid May 2017. |
For further information on our processes and methods, please see our CHTE processes and methods manual